Latest stories on NRSN
NeuroSense Advances PrimeC Toward December 2026 Health Canada Filing After Completing Pre-NDS Process
TipRanks63 · neutralproduct/pr
Neurosense Sees December 2026 As Filing Date For Nds For Primec
The Fly55 · neutralgeneral
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
PR Newswire63 · neutralproduct/pr
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
StockTitan73 · bullishproduct/pr
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" | NRSN Stock News
StockTitan63 · neutralproduct/pr
NeuroSense Hits Key TDP-43 Endpoint in Phase 2b ALS Trial, Advances Toward Phase 3
TipRanks73 · bullishproduct/pr
NeuroSense Posts Positive Phase 2 Biomarker Signals for PrimeC in Alzheimer’s Trial
TipRanks73 · bullishproduct/pr
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots | NRSN Stock News
StockTitan55 · neutralgeneral
NeuroSense Secures South Korean Patent for ALS Drug Candidate PrimeC
TipRanks67 · bullishproduct/pr
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS | NRSN Stock News
StockTitan67 · bullishproduct/pr
NeuroSense Therapeutics Wins Key Japanese Patent for ALS Drug PrimeC
TipRanks63 · neutralproduct/pr
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
PR Newswire63 · neutralproduct/pr
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition | NRSN Stock News
StockTitan63 · neutralproduct/pr
NeuroSense Therapeutics Advances Canadian Regulatory Talks on ALS Drug PrimeC
TipRanks63 · neutralproduct/pr